1
|
Prynn J, Alinaitwe R, Kimono B, Peto T, Ashton NJ, Steves CJ, Mugisha J, Prince M. Prevalence, aetiology, and service mapping of dementia in rural Uganda. Part of DEPEND Uganda (Dementia Epidemiology, unmet Need and co-Developing Solutions in Uganda).. Wellcome Open Res 2025; 9:544. [PMID: 39429626 PMCID: PMC11490832 DOI: 10.12688/wellcomeopenres.22944.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2025] [Indexed: 10/22/2024] Open
Abstract
Background Dementia prevalence in low- and middle-income countries is increasing, yet epidemiological data from African populations remain scarce. Crucial risk factors differ in Africa from more intensively studied global areas, including a higher burden of cerebrovascular disease and HIV, but lower rates of other risk factors like physical inactivity.Understanding dementia aetiology in African settings has been limited by the expensive and invasive nature of biomarker testing. This study leverages developments in blood-based and retinal imaging biomarker technology to examine the drivers of dementia in older Ugandans.People with dementia have complex needs benefiting from multi-dimensional support. Understanding current services will allow identification of barriers and opportunities to strengthen support available to people with dementia and their families. Methods The study is nested within the General Population Cohort run by the Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Research Unit. All adults aged 60+ (around 1400) are undergoing brief cognitive screening.In Part 1, cohort participants are selected based on screening scores to undergo detailed cognitive assessment, using methods developed by the 10/66 Dementia Research Group. Part 2 is a case control study of people with and without dementia using antecedent data, questionnaires, physical assessment, retinal imaging, and Alzheimer's blood-based biomarkers. We will also compare disability, frailty, quality of life, and social engagement in people with and without dementia.Part 3 assesses current formal support structures for people with dementia through review of publicly available literature and expert interviews. Conclusions This is the first study in Africa using blood-based and retinal imaging biomarkers to examine pathological processes underlying dementia, and systematically map services available for people with dementia. This paves the way for effective policy strategies and further focused research regarding both dementia prevention and support for affected people and their families.
Collapse
Affiliation(s)
- Josephine Prynn
- School of Life Course and Population Sciences, King's College London Faculty of Life Sciences & Medicine, London, England, UK
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, Uganda
| | - Racheal Alinaitwe
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, Uganda
- Makerere University School of Health Sciences, Kampala, Central Region, Uganda
| | - Beatrice Kimono
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, Uganda
| | - Tunde Peto
- School of Medicine, Dentistry, and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK
| | - Nicholas J Ashton
- Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- Banner Health, Phoenix, Arizona, USA
- King's College London Institute of Psychiatry Psychology & Neuroscience, London, England, UK
| | - Claire J Steves
- School of Life Course and Population Sciences, King's College London Faculty of Life Sciences & Medicine, London, England, UK
| | - Joseph Mugisha
- MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Central Region, Uganda
| | - Martin Prince
- School of Life Course and Population Sciences, King's College London Faculty of Life Sciences & Medicine, London, England, UK
| |
Collapse
|
2
|
Mikhailenko E, Colangelo K, Tuimala J, Kero M, Savola S, Raunio A, Kok EH, Tanskanen M, Mäkelä M, Puttonen H, Mäyränpää MI, Kumar D, Kaivola K, Paetau A, Tienari PJ, Polvikoski T, Myllykangas L. Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study. Brain 2025; 148:154-167. [PMID: 38938199 PMCID: PMC11706281 DOI: 10.1093/brain/awae212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 06/05/2024] [Accepted: 06/10/2024] [Indexed: 06/29/2024] Open
Abstract
Population-based cohort studies are essential for understanding the pathological basis of dementia in older populations. Previous studies have shown that limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) increases with age, but there have been only a few studies, which have investigated this entity in a population-based setting. Here we studied the frequency of LATE-NC and its associations with other brain pathologies and cognition in a population aged ≥ 85 years. The population-based Vantaa 85+ study cohort includes all 601 individuals aged ≥85 years who were living in Vantaa, Finland in 1991. A neuropathological examination was performed on 304 subjects (50.5%) and LATE-NC staging was possible in 295 of those. Dementia status and Mini-Mental State Examination (MMSE) scores were defined in the baseline study and three follow-ups (1994-99). The LATE-NC stages were determined based on TDP-43 immunohistochemistry, according to recently updated recommendations. Arteriolosclerosis was digitally assessed by calculating the average sclerotic index of five random small arterioles in amygdala and hippocampal regions, and frontal white matter. The association of LATE-NC with arteriolosclerosis and previously determined neuropathological variables including Alzheimer's disease neuropathologic change (ADNC), Lewy-related pathology (LRP), hippocampal sclerosis (HS) and cerebral amyloid angiopathy (CAA), and cognitive variables were analysed by Fisher's exact test, linear and logistic regression (univariate and multivariate) models. LATE-NC was found in 189 of 295 subjects (64.1%). Stage 2 was the most common (28.5%) and stage 3 the second most common (12.9%), whereas stages 1a, 1b and 1c were less common (9.5%, 5.1% and 8.1%, respectively). Stages 1a (P < 0.01), 2 (P < 0.001) and 3 (P < 0.001) were significantly associated with dementia and lower MMSE scores. LATE-NC was associated with ADNC (P < 0.001), HS (P < 0.001), diffuse neocortical LRP (P < 0.002), and arteriolosclerosis in amygdala (P < 0.02). In most cases LATE-NC occurred in combination alongside other neuropathological changes. There were only six subjects with dementia who had LATE-NC without high levels of ADNC or LRP (2% of the cohort, 3% of the cases with dementia), and five of these had HS. In all multivariate models, LATE-NC was among the strongest independent predictors of dementia. When LATE-NC and ADNC were assessed in a multivariate model without other dementia-associated pathologies, the attributable risk was higher for LATE-NC than ADNC (24.2% versus 18.6%). This population-based study provides evidence that LATE-NC is very common and one of the most significant determinants of dementia in the general late-life aged population.
Collapse
Affiliation(s)
| | - Kia Colangelo
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
| | - Jarno Tuimala
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
| | - Mia Kero
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | - Sara Savola
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | - Anna Raunio
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | - Eloise H Kok
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
| | - Maarit Tanskanen
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
| | - Mira Mäkelä
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
| | - Henri Puttonen
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | - Mikko I Mäyränpää
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | | | - Karri Kaivola
- Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, 00014 Finland
- Department of Neurology, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland
| | - Anders Paetau
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| | - Pentti J Tienari
- Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, 00014 Finland
- Department of Neurology, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland
| | - Tuomo Polvikoski
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
| | - Liisa Myllykangas
- Department of Pathology, University of Helsinki, 00014 Helsinki, Finland
- Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital, 00029 Helsinki, Finland
| |
Collapse
|
3
|
Burgueño-García I, López-Martínez MJ, Uceda-Heras A, García-Carracedo L, Zea-Sevilla MA, Rodrigo-Lara H, Rego-García I, Saiz-Aúz L, Ruiz-Valderrey P, López-González FJ, Guerra-Martín V, Rábano A. Neuropathological Heterogeneity of Dementia Due to Combined Pathology in Aged Patients: Clinicopathological Findings in the Vallecas Alzheimer's Reina Sofía Cohort. J Clin Med 2024; 13:6755. [PMID: 39597898 PMCID: PMC11594757 DOI: 10.3390/jcm13226755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2024] [Revised: 11/04/2024] [Accepted: 11/07/2024] [Indexed: 11/29/2024] Open
Abstract
Background/Objectives: Clinicopathological research in late-life dementia has focused recently on combined neurodegenerative and vascular conditions underlying the high phenotypic heterogeneity of patients. The Vallecas Alzheimer's Reina Sofía (VARS) cohort (n > 550), and particularly the series of associated brain donations (VARSpath cohort) are presented here. The aim of this study is to contribute to research in dementia with a well-characterized cohort from a single center. Methods: A total of 167 patients with complete neuropathological work-ups were analyzed here. The cohort is characterized by a high female predominance (79%), advanced age at death (88 yrs.), and a high frequency of ApoE-e4 haplotype (43%). Results: The main neuropathological diagnosis was Alzheimer's disease (79.6%), followed by vascular dementia (10.2%) and Lewy body dementia (6%). Overall, intermediate-to-high cerebrovascular disease was observed in 38.9%, Lewy body pathology in 57.5%, LATE (TDP-43 pathology) in 70.7%, ARTAG in 53%, and argyrophilic grain disease in 12% of the patients. More than one pathology with a clinically relevant burden of disease was present in 71.1% of the brains, and a selection of premortem neuropsychological and functional scores showed significant correlation with the number of co-pathologies identified in postmortem brains. Conclusions: The VARS cohort, with thorough clinical follow-up, regular blood sampling, 3-Tesla MR, and a high rate of postmortem brain donation, can provide essential multidisciplinary data in the rising age of modifying therapies and biomarkers for Alzheimer's disease and related dementias.
Collapse
Affiliation(s)
- Iván Burgueño-García
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - María José López-Martínez
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - Alicia Uceda-Heras
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - Lucía García-Carracedo
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - María Ascensión Zea-Sevilla
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | | | - Iago Rego-García
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - Laura Saiz-Aúz
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - Paloma Ruiz-Valderrey
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | - Francisco J. López-González
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| | | | - Alberto Rábano
- Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain; (I.B.-G.); (M.J.L.-M.); (A.U.-H.); (L.G.-C.); (M.A.Z.-S.); (I.R.-G.); (L.S.-A.); (P.R.-V.); (F.J.L.-G.)
| |
Collapse
|
4
|
Alafuzoff I, Libard S. Ageing-Related Neurodegeneration and Cognitive Decline. Int J Mol Sci 2024; 25:4065. [PMID: 38612875 PMCID: PMC11012171 DOI: 10.3390/ijms25074065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Revised: 03/27/2024] [Accepted: 04/03/2024] [Indexed: 04/14/2024] Open
Abstract
Neuropathological assessment was conducted on 1630 subjects, representing 5% of all the deceased that had been sent to the morgue of Uppsala University Hospital during a 15-year-long period. Among the 1630 subjects, 1610 were ≥41 years of age (range 41 to 102 years). Overall, hyperphosphorylated (HP) τ was observed in the brains of 98% of the 1610 subjects, and amyloid β-protein (Aβ) in the brains of 64%. The most common alteration observed was Alzheimer disease neuropathologic change (ADNC) (56%), followed by primary age-related tauopathy (PART) in 26% of the subjects. In 16% of the subjects, HPτ was limited to the locus coeruleus. In 14 subjects (<1%), no altered proteins were observed. In 3 subjects, only Aβ was observed, and in 17, HPτ was observed in a distribution other than that seen in ADNC/PART. The transactive DNA-binding protein 43 (TDP43) associated with limbic-predominant age-related TDP encephalopathy (LATE) was observed in 565 (35%) subjects and α-synuclein (αS) pathology, i.e., Lewy body disease (LBD) or multi system atrophy (MSA) was observed in the brains of 21% of the subjects. A total of 39% of subjects with ADNC, 59% of subjects with PART, and 81% of subjects with HPτ limited to the locus coeruleus lacked concomitant pathologies, i.e., LATE-NC or LBD-NC. Of the 293 (18% of the 1610 subjects) subjects with dementia, 81% exhibited a high or intermediate level of ADNC. In 84% of all individuals with dementia, various degrees of concomitant alterations were observed; i.e., MIXED-NC was a common cause of dementia. A high or intermediate level of PART was observed in 10 subjects with dementia (3%), i.e., tangle-predominant dementia. No subjects exhibited only vascular NC (VNC), but in 17 subjects, severe VNC might have contributed to cognitive decline. Age-related tau astrogliopathy (ARTAG) was observed in 37% of the 1610 subjects and in 53% of those with dementia.
Collapse
Affiliation(s)
- Irina Alafuzoff
- Department of Pathology, Uppsala University Hospital, 751 85 Uppsala, Sweden;
- Department of Immunology, Genetics and Pathology, Uppsala University, 751 05 Uppsala, Sweden
| | - Sylwia Libard
- Department of Pathology, Uppsala University Hospital, 751 85 Uppsala, Sweden;
- Department of Immunology, Genetics and Pathology, Uppsala University, 751 05 Uppsala, Sweden
| |
Collapse
|
5
|
Bermejo-Pareja F, del Ser T. Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. J Clin Med 2024; 13:536. [PMID: 38256670 PMCID: PMC10816332 DOI: 10.3390/jcm13020536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 12/29/2023] [Accepted: 01/04/2024] [Indexed: 01/24/2024] Open
Abstract
Background: The concept of Alzheimer disease (AD)-since its histological discovery by Alzheimer to the present day-has undergone substantial modifications. Methods: We conducted a classical narrative review of this field with a bibliography selection (giving preference to Medline best match). Results: The following subjects are reviewed and discussed: Alzheimer's discovery, Kraepelin's creation of a new disease that was a rare condition until the 1970's, the growing interest and investment in AD as a major killer in a society with a large elderly population in the second half of the 20th century, the consolidation of the AD clinicopathological model, and the modern AD nosology based on the dominant amyloid hypothesis among many others. In the 21st century, the development of AD biomarkers has supported a novel biological definition of AD, although the proposed therapies have failed to cure this disease. The incidence of dementia/AD has shown a decrease in affluent countries (possibly due to control of risk factors), and mixed dementia has been established as the most frequent etiology in the oldest old. Conclusions: The current concept of AD lacks unanimity. Many hypotheses attempt to explain its complex physiopathology entwined with aging, and the dominant amyloid cascade has yielded poor therapeutic results. The reduction in the incidence of dementia/AD appears promising but it should be confirmed in the future. A reevaluation of the AD concept is also necessary.
Collapse
Affiliation(s)
- Félix Bermejo-Pareja
- CIBERNED, Institute of Health Carlos III, 28029 Madrid, Spain
- Institute of Research i+12, University Hospital “12 de Octubre”, 28041 Madrid, Spain
| | - Teodoro del Ser
- Alzheimer’s Centre Reina Sofia—CIEN Foundation, Institute of Health Carlos III, 28031 Madrid, Spain;
| |
Collapse
|